Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
Spondyloarthritis
•
Myositis
•
Psoriatic arthritis
•
General Rheumatology
•
Scleroderma
•
SLE
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Related Questions
How do you approach managing nausea and GI side effects when initiating methotrexate?
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
How would you manage active severe psoriasis in a patient planning pregnancy, who also has psoriatic arthritis with well-controlled joint symptoms on certolizumab pegol (anti-TNF therapy)?
When do you consider Mesna for patients taking oral cyclophosphamide?
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
